Speaker Profile
Ph.D., Founder, CEO, Portal Bio
Biography
Dr. Armon Sharei is the Founder and Chief Executive Officer of Portal, a company dedicated to solving the massive challenge of cell permeability to advance drug discovery and cell therapy. Portal's approach uses mechanical disruption for intracellular delivery of diverse cargossuch as RNA, CRISPR, protein, and small moleculesinto various cell types, including hard-to-transfect patient-derived cells, without disrupting underlying cell function.Dr. Sharei is a proven biotech entrepreneur in the cell engineering field. Before founding Portal, he was the Founder and former CEO of SQZ Biotech, a company he led from its invention stage to a post-IPO status. His work at SQZ Biotech resulted in securing over $300 million in equity financing and establishing a collaboration with Roche valued at more than $1 billion. His deep scientific and business experience is central to Portal's mission to provide a simple, scalable, and universal platform for intracellular delivery for cell therapies, fundamental research, and bioproduction.
Talk
Portal: The Universal Platform for Intracellular Delivery
Portal is a universal platform solving the major challenge of cell permeability in drug discovery and cell therapy. Our simple, scalable mechanical disruption technology enables seamless intracellular delivery of diverse cargoes like CRISPR, RNA, and protein into various cell types. This is achieved while maintaining high cell viability, dramatically expanding therapeutic and research possibilities.
Emerging Therapeutics Showcase:
Portal Bio
Portal Biotechnologies is a cell engineering company dedicated to advancing drug discovery and cell therapy by overcoming the challenge of cell permeability. It employs a proprietary mechanical delivery platform that enables efficient, multiplexed intracellular delivery of diverse cargoes like RNA, CRISPR, and proteins into various cell types while maintaining high cell viability.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
